Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2024 09:00 ET | Source: Celularity, Inc.

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company), a biotechnology company developing allogeneic cell therapies and biomaterial products, today...
January 18, 2024 13:40 ET | Source: Celularity, Inc.

Celularity Releases CEO Letter to Shareholders

FLORHAM PARK, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is...
January 04, 2024 13:00 ET | Source: Celularity, Inc.

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products,...
January 03, 2024 12:00 ET | Source: Celularity, Inc.

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million...
November 24, 2023 13:15 ET | Source: Celularity, Inc.

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

FLORHAM PARK, N.J., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced...
October 18, 2023 09:00 ET | Source: Celularity, Inc.

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

SFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia FLORHAM PARK, N.J., Oct. 18, 2023 (GLOBE...
September 07, 2023 16:10 ET | Source: Celularity, Inc.

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and...
August 29, 2023 09:00 ET | Source: Celularity, Inc.

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapyAgreement underscores Celularity's demonstrated expertise in cell therapy...
July 27, 2023 09:07 ET | Source: Celularity, Inc.

Celularity Inc. Announces $3 Million Registered Direct Offering

FLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial...
July 27, 2023 09:00 ET | Source: Celularity, Inc.

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies...